AU702519B2 - Parenteral pharmaceutical compositions containing GF120918A - Google Patents

Parenteral pharmaceutical compositions containing GF120918A Download PDF

Info

Publication number
AU702519B2
AU702519B2 AU38913/95A AU3891395A AU702519B2 AU 702519 B2 AU702519 B2 AU 702519B2 AU 38913/95 A AU38913/95 A AU 38913/95A AU 3891395 A AU3891395 A AU 3891395A AU 702519 B2 AU702519 B2 AU 702519B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
safe
effective amount
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38913/95A
Other languages
English (en)
Other versions
AU3891395A (en
Inventor
Wei-Qin Tong
Mickey Lee Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of AU3891395A publication Critical patent/AU3891395A/en
Application granted granted Critical
Publication of AU702519B2 publication Critical patent/AU702519B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU38913/95A 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing GF120918A Ceased AU702519B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31830894A 1994-10-05 1994-10-05
US08/318308 1994-10-05
PCT/US1995/012952 WO1996011007A1 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a

Publications (2)

Publication Number Publication Date
AU3891395A AU3891395A (en) 1996-05-02
AU702519B2 true AU702519B2 (en) 1999-02-25

Family

ID=23237614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38913/95A Ceased AU702519B2 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing GF120918A

Country Status (12)

Country Link
EP (1) EP0784474A2 (pt)
JP (1) JPH10507177A (pt)
KR (1) KR970705997A (pt)
AU (1) AU702519B2 (pt)
BR (1) BR9509251A (pt)
CA (1) CA2201628A1 (pt)
CZ (1) CZ104197A3 (pt)
HU (1) HUT77883A (pt)
NZ (1) NZ295546A (pt)
PL (1) PL319511A1 (pt)
RU (1) RU2157687C2 (pt)
WO (1) WO1996011007A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
HUP0104280A3 (en) 1998-10-08 2002-07-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
AT408186B (de) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag Wässerige zubereitung von beta-carotin
DE60045114D1 (de) 1999-05-17 2010-11-25 Cancer Res Ventures Ltd Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
ES2253398T3 (es) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. Camptotecinas liposomales mejoradas y sus usos.
WO2003002150A1 (en) * 2001-06-28 2003-01-09 Wyeth Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783680B2 (ja) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体

Also Published As

Publication number Publication date
WO1996011007A1 (en) 1996-04-18
PL319511A1 (en) 1997-08-18
HUT77883A (hu) 1998-09-28
NZ295546A (en) 1999-01-28
CZ104197A3 (en) 1997-09-17
JPH10507177A (ja) 1998-07-14
AU3891395A (en) 1996-05-02
KR970705997A (ko) 1997-11-03
CA2201628A1 (en) 1996-04-18
MX9702473A (es) 1997-07-31
EP0784474A2 (en) 1997-07-23
BR9509251A (pt) 1997-10-21
RU2157687C2 (ru) 2000-10-20

Similar Documents

Publication Publication Date Title
JP7196373B2 (ja) 安定なニモジピン非経口製剤
EP1052974B1 (en) Pharmaceutical formulation containing epothilone
JP4890732B2 (ja) 癌治療用パクリタキセル・リポソーム組成物およびその製造方法
US10688111B2 (en) Liquid formulations of compounds active at sulfonylurea receptors
US7915317B2 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
AU702519B2 (en) Parenteral pharmaceutical compositions containing GF120918A
US10799486B2 (en) Stable nimodipine parenteral formulation
AU2011264919A1 (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
EP2310009B1 (en) Parenteral and oral formulations of benzimidazoles
KR102656841B1 (ko) 레파뮬린의 주사가능한 약제학적 제형
WO2018047074A1 (en) Sterile injectable compositions comprising drug micelles
WO2005021046A1 (en) Compositions and methods for delivery of biologically active agents
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
JP2011529930A (ja) 注射可能タキサン医薬品組成物
JP2008521834A (ja) 治療学的処方物
RU2236227C1 (ru) Устойчивая фармацевтическая форма противоракового препарата
MXPA97002473A (en) Parenteral pharmaceutical compositions containing gf1209
US20240156829A1 (en) Stable Antiemetic Emulsions for Parenteral Administration
CN1164189A (zh) 含有gf120918a的非肠道药物组合物
WO2024127418A1 (en) Injectable compositions of posaconazole
TW202430147A (zh) 包含高濃度奧匹蘭色林的醫藥組成物
KR20240074687A (ko) 고농도의 오피란제린을 포함하는 약제학적 조성물
WO2021044328A1 (en) Cabazitaxel liquid formulations
CN117598986A (zh) 一种卡巴他赛自组装脂质纳米注射组合物及制备方法
JP2024537910A (ja) 安定した希釈準備済みカルフィルゾミブ組成物

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired